- Home
- LPRO vs CBIO Comparison
LPRO vs CBIO Comparison
Compare LPRO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- CBIO
- Stock Information
- Founded
- LPRO 2000
- CBIO 2003
- Country
- LPRO United States
- CBIO United States
- Employees
- LPRO N/A
- CBIO N/A
- Industry
- LPRO Finance: Consumer Services
- CBIO
- Sector
- LPRO Finance
- CBIO
- Exchange
- LPRO Nasdaq
- CBIO Nasdaq
- Market Cap
- LPRO 252.9M
- CBIO 218.2M
- IPO Year
- LPRO N/A
- CBIO N/A
- Fundamental
- Price
- LPRO $1.80
- CBIO $12.87
- Analyst Decision
- LPRO Buy
- CBIO Strong Buy
- Analyst Count
- LPRO 6
- CBIO 5
- Target Price
- LPRO $3.00
- CBIO $25.60
- AVG Volume (30 Days)
- LPRO 660.9K
- CBIO 120.1K
- Earning Date
- LPRO 11-06-2025
- CBIO 11-23-2025
- Dividend Yield
- LPRO N/A
- CBIO N/A
- EPS Growth
- LPRO N/A
- CBIO N/A
- EPS
- LPRO N/A
- CBIO N/A
- Revenue
- LPRO $16,254,999.00
- CBIO N/A
- Revenue This Year
- LPRO $306.78
- CBIO N/A
- Revenue Next Year
- LPRO $11.69
- CBIO N/A
- P/E Ratio
- LPRO N/A
- CBIO N/A
- Revenue Growth
- LPRO N/A
- CBIO N/A
- 52 Week Low
- LPRO $0.70
- CBIO $9.81
- 52 Week High
- LPRO $6.92
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- LPRO 39.97
- CBIO 55.07
- Support Level
- LPRO $1.78
- CBIO $12.31
- Resistance Level
- LPRO $1.98
- CBIO $13.27
- Average True Range (ATR)
- LPRO 0.13
- CBIO 0.84
- MACD
- LPRO -0.01
- CBIO 0.16
- Stochastic Oscillator
- LPRO 15.28
- CBIO 88.44
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.